• Telehealth
• Policy
• Compounding
• FDA

Hims is bringing peptides to millions later this month. BPC-157 is next in line.

By Peptide Policy Watch staff · Published November 10, 2026 · Updated November 11, 2026 · 8 min read · 5 sources, 4 checked at the source

You've heard the names in the gym, on podcasts, and in group chats: sermorelin, NAD, BPC-157, TB-500. On November 9, 2026, a major U.S. telehealth company put a date on them.

Hims & Hers, which reported nearly 2.8 million subscribers last quarter, says its Peptides+ offering launches "later this month." [V] [S] First up are sermorelin, glutathione and NAD. [S] The company says it will make raw peptide ingredients at a plant it acquired in Menlo Park. [S] The same day, Andrew Huberman, the Stanford neuroscientist behind the Huberman Lab podcast, joined its board. [V]

The two names people ask about most in wellness circles, BPC-157 and TB-500, are already in the queue. Hims says those arrive "when the regulatory environment permits." [S]

That is a big moment. For years, peptides sat in a narrower lane: clinic menus, locker-room talk, and company plans labeled "when allowable." A publicly traded telehealth company putting them on a November calendar, building its own ingredient plant in California, and adding a very public science voice to its board is how that narrower conversation starts to look mainstream.

Facts are as of November 10, 2026. Sources, with retrieval dates, are at the bottom. Call quotations are from a third-party transcript and are labeled [S].

Updated November 10, 2026. The same week, DataMEDS said its Corexa Pharmacy made a first sale of one of the six HHS peptides. That report is in a new article. For the research and compounding status of the three names in Hims's first phase, see our side-by-side page on sermorelin, glutathione and NAD.

Updated November 11, 2026. A scoreboard of who has announced what — Enhanced, Hims and DataMEDS — is in a new article. B12 and L-carnitine, two other names on the October 29 Peptides+ preview list, are covered in a side-by-side research and status page.

• later this monthHims's window for the first Peptides+ phase (earnings call, Nov. 9) [S]
• 2.8 millionHims subscribers last quarter [V]
• Nov. 13last day to comment on the HHS draft (11:59 PM ET) [V]

What's coming, and when

On the November 9 earnings call, CFO Oluyemi Okupe said the first phase of the peptide offering would include sermorelin, glutathione and NAD, later this month. [S] CEO Andrew Dudum called it "Peptides Plus" and "end of this month." In the question-and-answer session he also named B12 alongside those first three. [S] In a letter posted the same day, he wrote: "Next is Peptides+, with clinician-led treatment plans and access to regular blood testing to monitor progress." [V]

BPC-157 and TB-500 come after that, "when the regulatory environment permits," Okupe said. [S] Dudum made the same point: those two join the platform as they become allowed. [S]

That date is the new part. In an October 29 newsroom post, covered in our November 3 article on Hims and the six-peptide policy, the company had already listed sermorelin, glutathione, B12, NAD+ and L-carnitine, "with BPC-157 and TB-500 to follow when allowable." [S] That was a plan. November 9 is when executives put it on the calendar.

Okupe also said he does not expect peptide sales to amount to a material share of fourth-quarter results. [S] The official Q3 earnings release reported $890.4 million in revenue, up 49% from a year earlier, and a $33.0 million net loss. It did not mention peptides. [V] The launch window, the product list, and the plant came from the call and the CEO's letter.

The plant is part of the story, not a footnote. Dudum said Hims had bought a Menlo Park facility and folded it into the company, and that it intends to make the raw active ingredients for peptides such as BPC-157 and TB-500 there. Existing supply chains for those ingredients, he said, are "not really at the quality that we'd like to see." [S] An October 29 newsroom post had already said the company had built a U.S.-based peptide manufacturing facility. [S] The November 9 call is the first time, in the sources opened for this article, that Menlo Park was named as the site. [U]

Huberman's appointment landed the same day. Hims said he joins the board and will also advise the company on science and brand marketing. [V] Dudum told listeners that Huberman had been advising on clinical standards and lab testing for the peptide offering. [S] Those are the company's statements about a board seat and an advisory role, not an evaluation of any peptide.

For a sense of how sermorelin's status differs from BPC-157 and TB-500, see our Sermorelin and Geref explainer.

What to watch next

Three calendar items matter now.

The launch itself. Hims said "later this month" and, in one remark, "end of this month." [S] Watch whether that first phase actually appears in November, and whether the live offering matches the list from the call: sermorelin, glutathione and NAD, with B12 also named.

November 13, 2026, at 11:59 PM Eastern. That is the close of public comments on regulations.gov docket HHS-OASH-2026-0496, the HHS draft that covers six peptides, including BPC-157 and TB-500. [V] After the docket closes, watch whether HHS revises the draft, finalizes it, or leaves it as a draft.

BPC-157 and TB-500. Hims has them in line, not on the first-phase calendar. The company's own wording is that they wait on the regulatory environment. [S] A finalized HHS policy, or a decision by Hims that it is ready, would be the next signal.

The policy sitting in the background

Asked what the company is still waiting for, Dudum pointed to the open comment period. He said he expected comments to be gathered in the coming weeks, and then more detail on the testing and facility standards Hims would need to meet, which would give the company a clearer view of the path ahead. [S]

The document behind that wait is HHS's draft "Enforcement Discretion Policy Regarding 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry Compounding Using Certain Peptide Bulk Drug Substances," published in the Federal Register on October 30, 2026, at 91 FR 68526. [V] It is a draft policy on how HHS proposes to exercise enforcement discretion for 503A compounding, not a formal FDA proposed rule and not a final decision. [V] It names six peptides — BPC-157, TB-500, epitalon, KPV, MOTS-c and semax — and sets ten conditions a state-licensed 503A pharmacy would have to meet. [V] It does not add a single peptide to FDA's 503A bulks list. That list still has its own rulemaking. Our November 3 explainer and the Federal Register comment-period page walk through the distinction.

Closing the comment docket on November 13 does not, by itself, create an FDA rule or an approval. A draft enforcement-discretion policy can be revised, finalized, or left as a draft. [V] None of those outcomes is the same as adding a substance to the bulks list. Hims can also set its own timing. [U]

A launch window is not an FDA approval, and a telehealth company's catalog is not the 503A bulks list. The six peptides in the HHS draft are still unapproved for these uses. [V] The October 30 Federal Register notice describes an enforcement-discretion policy, not an approval, and finalizing the draft as written would not change that. [V]

The earnings-call remarks come from a Benzinga transcript, not an official company transcript, so those lines are labeled [S]. The financial figures and the board announcement are from Hims's own November 9 pages. [V] This page does not recommend any product, and it does not link to a sales page.

The useful test now is a simple one. Did the first phase actually show up later this month? And did BPC-157 and TB-500 stay in line, or did the regulatory picture shift after November 13?

Sources (retrieved November 10, 2026 unless noted)

1. Hims & Hers Health, "Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results," November 9, 2026 [V] — https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Third-Quarter-2026-Financial-Results/default.aspx
2. Andrew Dudum, "How We're Building the Customer Relationship in Health," Hims & Hers newsroom, November 9, 2026 [V] — https://news.hims.com/newsroom/how-were-building-the-customer-relationship-in-health
3. Hims & Hers, "Dr. Andrew Huberman Joins Hims & Hers Board of Directors," November 9, 2026 [V] — https://news.hims.com/newsroom/dr-andrew-huberman-joins-hims-hers-board-of-directors
4. Benzinga, "Hims & Hers Health Q3 2026 Earnings Call Transcript," November 9, 2026, 6:09 PM ET [S] (third-party transcript, not an official company transcript) — https://www.benzinga.com/news/26/11/63076365/hims-hers-health-q3-2026-earnings-call-transcript
5. Federal Register, 91 FR 68526, HHS draft enforcement-discretion policy on 503A compounding with certain peptide bulk drug substances, October 30, 2026 [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits